Search Results

You are looking at 1 - 10 of 44 items for :

  • "hepatitis C virus" x
  • Refine by Access: All x
Clear All
Full access

Harrys A. Torres, Parag Mahale, Boris Blechacz, Ethan Miller, Ahmed Kaseb, H. Franklin Herlong, Nathan Fowler, Ying Jiang, Issam I. Raad, and Dimitrios P. Kontoyiannis

Background Approximately 130 to 170 million persons globally are infected with hepatitis C virus (HCV). 1 In the United States, approximately 2.7 to 3.9 million persons (1.0%–1.5%) are infected. 2 Chronic HCV increases the risk for mortality

Full access

Harrys A. Torres, Lillian R. Roach, Parag Mahale, Minas P. Economides, Boris Blechacz, Ethan Miller, Roy Borchardt, Anis Rashid, Thein H. Oo, Bhavarth Shukla, Malik Farida, Charles D. Ericsson, Bruno P. Granwehr, and Issam I. Raad

Hepatitis C virus (HCV) infection is a major problem worldwide, with 230 million reported cases, including 2.7 to 3.9 million cases (1.0%–1.5%) in the United States. 1 The prevalence rates for HCV infection in patients with cancer range from 1

Full access

Presenter: Stephen D. Smith

etiology of MZL, current treatment standards by subtype, and the role of targeted therapies ( Figure 1 ). Figure 1. Diagnosis of MZLs. Abbreviations: BM, bone marrow; CLL, chronic lymphocytic leukemia; HBV, hepatitis B virus; HCV, hepatitis C virus; FL

Full access

Caitlin A. Hester, Nicole E. Rich, Amit G. Singal, and Adam C. Yopp

the United States. 1 – 4 Typically occurring in a background of chronic liver disease and cirrhosis, the most common risk factors worldwide have traditionally included hepatitis B virus (HBV), hepatitis C virus (HCV), and alcohol-related liver disease

Full access

Matthias Holdhoff, Maciej M. Mrugala, Christian Grommes, Thomas J. Kaley, Lode J. Swinnen, Carlos Perez-Heydrich, and Lakshmi Nayak

-C, cytarabine; CSF, cerebrospinal fluid; HBV, hepatitis B virus; HCT/ASCT, high-dose chemotherapy and autologous stem cell transplant; HCV, hepatitis C virus; MTX, methotrexate; WBRT, whole-brain radiation therapy. Once the diagnosis is confirmed, treatment must

Full access

Kwang-Yu Chang, Jang-Yang Chang, and Yun Yen

infection: epidemiology and vaccination . Epidemiol Rev 2006 ; 28 : 112 – 125 . 25 Shepard CW Finelli L Alter MJ . Global epidemiology of hepatitis C virus infection . Lancet Infect Dis 2005 ; 5 : 558 – 567 . 26 Shin HR Lee CU

Full access

Laura M. Kulik

. Secondary prevention of hepatitis c virus-related hepatocellular carcinoma [editorial] . J Gastroenterol Hepatol 2005 ; 20 : 1475 – 1477 . 6. Yao FY Bass NM Nikolai B . A follow-up analysis of the pattern and predictors of dropout from the

Full access

Andrew D. Zelenetz, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nishitha Reddy, Lubomir Sokol, Lode Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary A. Dwyer, and Maoko Naganuma

]). Hepatitis C Virus-Associated B-Cell NHL Case-control studies have shown a strong association between seropositivity for hepatitis C virus (HCV) and development of NHL, particularly for B-cell lymphomas. 72 - 80 In large population-based or multicenter

Full access

2 baseline/change with tivozanib and use modeling to correlate exposure with biomarker change and the primary outcome measure of PFS Determine the change in viral load (hepatitis B virus [HBV] and hepatitis C virus [HCV]) during therapy in patients

Full access

toxicity and tolerability of the combination of temsirolimus plus sorafenib Describe TTP, PFS, OS, response rate, AFP response, and toxicity and tolerability in subsets defined by hepatitis B virus, hepatitis C virus, Asian, and non-Asian status